Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial
Titel:
Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial
Auteur:
Di Leo, Angelo Johnston, Stephen Lee, Keun Seok Ciruelos, Eva Lønning, Per E Janni, Wolfgang O'Regan, Ruth Mouret-Reynier, Marie-Ange Kalev, Dimitar Egle, Daniel Csőszi, Tibor Bordonaro, Roberto Decker, Thomas Tjan-Heijnen, Vivianne C G Blau, Sibel Schirone, Alessio Weber, Denis El-Hashimy, Mona Dharan, Bharani Sellami, Dalila Bachelot, Thomas